{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-087221","form_type":"8-K","ticker":"COCH","cik":"0001840877","company_name":"Envoy Medical, Inc.","filed_at":"2026-08-10T20:01:14+00:00","discovered_at":"2026-08-10T20:03:11.445329+00:00","generated_at":"2026-08-10T20:03:43.901856+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Envoy Medical posts Q2 loss, submits first FDA PMA module for Acclaim implant","bullets":["Q2 2026 net loss of $7.27M ($0.07/share) vs $6.94M ($0.32/share) in Q2 2025; revenue only $51K.","Submitted first of four modular PMA modules to FDA for Acclaim cochlear implant; final module targeted Q2 2027.","12-month Stage 1 data: mean CNC word score 53.2% vs 15.2% baseline (38.0 pp gain), up from 24.0 pp at 6 months.","R&D spending rose to $3.13M from $2.49M on clinical trial and PMA work; cash ~$19.7M at June 30.","Terminated $15M ATM equity facility; 4 patents granted in Australia and Europe."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-087221","json":"https://secwatch.observer/filing/0001213900-26-087221.json","markdown":"https://secwatch.observer/filing/0001213900-26-087221.md","text":"https://secwatch.observer/filing/0001213900-26-087221.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840877/000121390026087221/0001213900-26-087221-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840877/000121390026087221/ea0301372-8k_envoy.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:03:43.901856+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}